MUC1 Promoter–Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer

Abstract

Mucin1 (MUC1) is overexpressed in pancreatic ductal adenocarcinoma (PDA) and is associated with tumor aggressiveness, suggesting that MUC1 is a promising therapeutic target for promoter-driven diphtheria toxin A (DTA). Endogenous MUC1 transcript levels were analyzed by quantitative PCR (qPCR) in multiple PDA cells (Capan1, HPAFII, Su.86.86, Capan2, Hs766T, MiaPaCa2, and Panc1). Expression levels were correlated with luciferase activity and cell death after transfection with MUC1 promoter-driven luciferase and DTA constructs. MUC1-positive (þ) cells had significantly elevated MUC1 mRNA expression compared with MUC1-negative (À) cells. Luciferase activity was significantly higher in MUC1 þ cells when transfected with MUC1 promoter-driven luciferase and MUC1 þ cells underwent enhanced cell death after transfection with a single dose of MUC1 promoter-driven DTA. IFNg pretreatment enhanced MUC1 expression in MUC1 À cells and induced sensitivity to MUC1-DTA therapy. Matched primary and metastatic tumor lesions from clinical specimens revealed similar MUC1 IHC labeling patterns, and a tissue microarray of human PDA biopsies revealed increased immunolabeling with a combination of MUC1 and mesothelin (MSLN) antibodies, compared with either antibody alone. Combining MUC1 with MSLN-targeted DTA enhanced drug efficacy in an in vitro model of heterogeneous PDA. These data demonstrate that MUC1 promoter-driven DTA preferentially kills MUC1-expressing PDA cells and drugs that enhance MUC1 expression sensitize PDA cells with low MUC1 expression.Implications: MUC1 expression in primary and metastatic lesions provides a rationale for the development of a systemic MUC1 promoter-driven DTA therapy that may be further enhanced by combination with other promoter-driven DTA constructs. Mol Cancer Res; 13(3); 439-48. Ó2014 AACR.

RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion

“…Utilizing a pancreatic cancer-specific promoter such as the Mucin1 Promoter (MUC1) to control E1A expression also enhanced the replication selectivity in pancreatic cancer. 44 Systemic administration of oncolytic adenoviruses has favorable toxicity profiles in cancer patients. DNX-2401, which has received fast-track FDA approval, is an orphan drug for the treatment of malignant glioma.…”

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells

“…A PDA tumor tissue microarray was constructed using formalin-fixed, paraffin-embedded PDA samples of Institutional Review Board-consented patients at the TJU Hospital (Philadelphia, PA, USA). 70 Surgical pathologists confirmed the diagnosis for each case and representation of the tumor area in the tissue microarray. Detection of HuR, PIM1, and carbonic anhydrase IX were performed in serial sections (4 μm) using the following antibodies: mouse monoclonal 3A2 HuR antibody (Santa Cruz Biotechnologies) at 1:500, rabbit monoclonal anti-PIM1 antibody (Abcam) at 1:200 and rabbit polyclonal anti-CAIX (Novus Biologicals, Littleton, CO, USA) at 1:1000.…”

A double safety lock tumor-specific device for suicide gene therapy in breast cancer

“…The 5TR1 aptamer binds to the aberrantly hypoglycosilated MUC1 located on the breast cancer-cell surface. The second lock corresponds to the hMUC1 promoter, which ensures expression of the cytotoxic ricin with the preprotrypsin leader only in MUC1 overexpressing cells [53,54].…”